BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, March 4, 2026
See today's BioWorld MedTech
Home
» Therapanacea develops AI solution to quantify the severity of lung damage from COVID-19
To read the full article
sign up for free
or
sign in
.
AI solution for prognosis of COVID-19 pneumonia
Therapanacea develops AI solution to quantify the severity of lung damage from COVID-19
Oct. 12, 2020
By
Bernard Banga
PARIS – A consortium that includes Therapanacea SAS, GE Healthcare France SAS, Orange Healthcare SA, the AP-HP group of 39 hospitals in the Paris region and the French academic society for thoracic imaging has created a database for COVID-19.
Medical technology
Diagnostics
Artificial intelligence
Digital health
Respiratory
Coronavirus
Europe